Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Product › Details

ATX-GD-59 (Apitope)

	Next higher product group	immunotherapy_o
	Status	2017-10-31 development p1 existent
	Organisation	Apitope International N.V.
	Group	Apitope (Group)
	Source	Apitope International N.V.. (10/31/17). "Press Release: Apitope Announces Its Intention to Launch an Initial Public Offering and Listing on Euronext Brussels [Not for release in US, AU, CA, JP or any other jurisdiction where prohibited by applicable law]

Record changed: 2023-07-10

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for immunotherapy_o

[1] Technische Universität München. (11/28/22). "Press Release: Nanoswitches for Tumor Targeting. TUM Spin-off Plectonic Develops Antibody-based Immunotherapies"....
[2] Strike Pharma AB. (4/28/21). "Press Release: Personalised Immunotherapy Start-up Strike Pharma Appoints Industry Veteran Mårten Winge as New CEO". Uppsala....
[3] Medigene AG. (1/13/21). "Press Release: Medigene Expands Patent Protection of Its Technologies in Key Markets, the USA and Europe". Planegg-Martinsried....
[4] Aimmune Therapeutics, Inc.. (3/25/19). "Press Release: European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint. Company Intends to Submit European MAA in Mid-2019". Brisbane, CA....
[5] Aimmune Therapeutics, Inc.. (2/28/19). "Press Release: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights". Brisbane, CA....
[6] Aimmune Therapeutics, Inc.. (11/12/18). "Press Release: Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science". Brisbane, CA....
[7] Apitope International N.V.. (10/24/18). "Press Release: Apitope Announces Management Changes. Keith Martin to Retire as CEO, Continue as Non-Executive Director – Hayley French Appointed COO and Interim CEO". Hasselt & Chepstow....
[8] Aimmune Therapeutics, Inc.. (10/15/18). "Press Release: Aimmune Therapeutics Announces Initiation of Phase 2 Study with Regeneron and Sanofi of AR101 with Adjunctive Dupilumab in Peanut-Allergic Patients". Brisbane, CA....
[9] Aimmune Therapeutics, Inc.. (6/11/18). "Press Release: Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO". Brisbane, CA....
[10] Aimmune Therapeutics, Inc.. (3/12/18). "Press Release: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results". Brisbane, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]